Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Raymond Shaheen

Vascular Surgery Mountain View, CA Medical Doctor

NPI 1114997434 CMS profile 277342

305 South Dr, Suite 7, Mountain View, CA 94040

Open in the dashboard

General payments

$13,664

121 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Raymond Shaheen of Mountain View, CA is reported in the CMS Open Payments database as having received $13,664 across 121 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $380 16
2024 General $436 16
2023 General $1,380 18
2022 General $207 10
2021 General $390 11
2020 General $369 16
2019 General $10,502 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Raymond Shaheen
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Raymond Shaheen were reported at $380. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Raymond Shaheen Vascular Surgery median Middle half National median
2019 $10,502 $796 $226–$2,363 $163
2020 $369 $348 $118–$1,110 $114
2021 $390 $471 $158–$1,421 $132
2022 $207 $725 $222–$2,183 $149
2023 $1,380 $836 $257–$2,440 $160
2024 $436 $909 $252–$2,619 $164
2025 $380 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $4,826 3 payments
  2. Smith+Nephew, Inc. $4,275 35 payments
  3. Medtronic, Inc. $1,323 13 payments
  4. Osiris Therapeutics Inc. $1,176 6 payments
  5. Janssen Pharmaceuticals, Inc $672 17 payments
  6. Organogenesis Inc. $304 12 payments
  7. PolarityTE, Inc. $168 1 payment
  8. MIMEDX Group, Inc. $163 6 payments
  9. Medtronic Vascular, Inc. $127 1 payment
  10. Musculoskeletal Transplant Foundation Inc. $117 4 payments
  11. Other $513 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $4,813 2 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,500 1 payment
  3. Food and Beverage $3,309 110 payments
  4. Travel and Lodging $2,041 8 payments
Products named General payments · program years 2019–2025
  1. EVLT $4,813 2 payments
  2. GRAFIX $4,766 12 payments
  3. Stravix $4,728 11 payments
  4. GrafixPL $3,634 6 payments
  5. TurboHawk $1,256 12 payments
  6. Grafix PL PRIME $1,115 5 payments
  7. XARELTO $672 17 payments
  8. Santyl $221 9 payments
  9. REGRANEX $186 7 payments
  10. COLLAGENASE SANTYL $170 8 payments
  11. Other $1,818 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

238

Median for Vascular Surgery: 122

Drug cost

$13,489

Median for Vascular Surgery: $14,135

Branded share of claims

19.3%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 13 $9,341
Pentoxifylline Generic 68 $2,388
Cilostazol Generic 72 $871
Doxycycline Hyclate Generic 14 $538
Gabapentin Generic 19 $164
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 11 $66
Atorvastatin Calcium Generic 19 $66
Clopidogrel Clopidogrel Bisulfate Brand 22 $54

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 90 billing codes

Paid by Medicare

$589,998

Of which drugs: $170,299

Medicare patients

278

Average age 77

Services billed

3,285

146 women, 132 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Ischemic heart disease 31%
Atrial fibrillation 29%
Diabetes 27%
Chronic kidney disease 24%
Osteoporosis 22%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Epifix, per square centimeter Q4186 Office 19 1,109 $133,260

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

121 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record